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AbstrACt
background Migration is a major global driver of 
population change. Certain migrants may be at increased 
risk of infectious diseases, including tuberculosis (TB), HIV, 
hepatitis B and hepatitis C, and have poorer outcomes. 
Early diagnosis and management of these infections can 
reduce morbidity, mortality and onward transmission and 
is supported by national guidelines. To date, screening 
initiatives have been sporadic and focused on individual 
diseases; systematic routine testing of migrant groups for 
multiple infections is rarely undertaken and its impact is 
unknown. We describe the protocol for the evaluation of 
acceptability, effectiveness and cost-effectiveness of an 
integrated approach to screening migrants for a range of 
infectious diseases in primary care.
Methods and analysis We will conduct a mixed-
methods study which includes an observational cohort 
with interrupted time-series analysis before and after the 
introduction of routine screening of migrants for infectious 
diseases (latent TB, HIV, hepatitis B and hepatitis C) when 
first registering with primary care within Leicester, UK. 
We will assess trends in the monthly number and rate of 
testing and diagnosis for latent TB, HIV, hepatitis B and 
hepatitis C to determine the effect of the policy change 
using segmented regression analyses at monthly time-
points. Concurrently, we will undertake an integrated 
qualitative sub-study to understand the views of migrants 
and healthcare professionals to the new testing policy 
in primary care. Finally, we will evaluate the cost-
effectiveness of combined infection testing for migrants in 
primary care.
Ethics and dissemination The study has received HRA 
and NHS approvals for both the interrupted time-series 
analysis (16/SC/0127) and the qualitative sub-study (16/
EM/0159). For the interrupted time-series analysis we 
will only use fully anonymised data. For the qualitative 
sub-study, we will gain written, informed, consent. 
Dissemination of the results will be through local and 
national meetings/conferences as well as publications in 
peer-reviewed journals.
IntroduCtIon 
Migration is an important determinant 
of population change in the UK. Office 
for National Statistics estimates indicate 
that between 1991 and 2011, median 
strengths and limitations of this study
 ► Integrated analysis encompassing interrupted 
time-series, qualitative and health-economic anal-
ysis of a combined infection screening programme 
for migrants.
 ► Using routine primary care infection testing data be-
fore and after the introduction of a new combined 
infection screening programme for migrants.
 ► Integrated qualitative and health economic anal-
ysis providing important information about what 
migrants and healthcare professionals think about 
combined infection testing and also whether com-
bined testing is cost-effective.
 ► Combined infection testing programme currently 
limited to high risk migrant populations.
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annual migration to the UK was 158 000 people 
(IQR: 76 000–198 000 people) with a median of 57.5% 
(IQR: 54.7%–65.9%) of migrants arriving from outside 
the European Union (31.7% from Africa and the Indian 
subcontinent).1 Consequently, in 2012, 12.4% of the UK 
population was born overseas; roughly half (4.5 million) 
were born outside Europe, North America.2 Large UK 
urban conurbations have higher levels of migration 
and therefore larger overseas-born populations. For 
example, in Leicester, one of the most ethnically diverse 
UK cities,3 approximately 30% of the population is born 
outside Europe and North America, and individuals 
from the Indian subcontinent alone make up 15% of the 
population.3 
Migrants are a heterogeneous group, characterised by 
specific language and cultural identities4 with specific 
health needs.5 6 Although the evidence-base remains 
limited, data indicate that overseas-born migrants 
(primarily from Africa and Asia1), as compared with the 
UK born population, are at an increased risk of, and 
disproportionately affected by, certain communicable 
diseases—including tuberculosis (TB), HIV, hepatitis B 
and hepatitis C.7 8 Between 1998 and 2012, UK-TB noti-
fications increased by 55%.9 10 However, most of this 
increase has been among those born outside the UK, in 
whom notifications have risen by 106%9 10; foreign-born 
migrants account for over 70% of UK-TB notifications and 
have a 20-fold higher TB incidence than UK-born indi-
viduals.9 10 Overseas-born migrants from certain regions 
such as sub-Saharan Africa and Southeast Asia are also 
at increased risk from blood-borne viruses and account 
for over 50% of newly diagnosed cases of HIV,11 12 80% 
of hepatitis B infected UK blood donors and 50% of 
hepatitis C infected UK blood donors.6 However, sero-
prevalence data for these infections among UK migrant 
populations are limited.
Data on the outcomes from these communicable 
diseases suggests that migrants are more likely to 
present late (eg, HIV-infection8 13 individuals born over-
seas are significantly more likely to present with CD4 
counts <350 cells/mm3), have more aggressive disease 
processes (HIV and TB8 13–16) and are likely to transmit 
to contacts if undiagnosed (in the case of communicable 
diseases5 17 18).
Early diagnosis and management of communicable 
diseases can, therefore, result in improved outcomes by 
preventing morbidity, mortality and onward transmis-
sion.19 This position is supported by several guidelines 
from the National Institute for Health and Care Excel-
lence (NICE) and other national/international bodies 
which advocate screening migrants for active and latent 
TB,17 HIV (which exemplifies a shift towards universal 
HIV testing in high prevalence areas [>2/1000]),20–22 
hepatitis B18 23 24 and hepatitis C.18 23 24 Operationalising a 
systematic/co-ordinated method of identifying infectious 
diseases that are prevalent in migrants, while desirable,25 
has not been undertaken to date with the exception of 
latent TB with previous UK work showing that identifying 
latent TB in migrants from countries with an interme-
diate TB incidence (>150 cases/100 000 population per 
year) when first registering with primary care would be 
feasible and cost-effective for the National Health Service 
(NHS).19 26 27 Recent work from London has shown that 
identifying viral hepatitis, although in a mixed migrant 
and non-migrant population, was feasible and cost-ef-
fective.28 Currently, however, routine migrant testing 
for infectious diseases remains limited despite it being 
acceptable to migrant communities which may reflect 
concerns about implementation, costs and resource 
implications.29 30
Although the new Collaborative Tuberculosis Strategy 
for England recommends identifying latent TB in migrants 
(from countries with TB incidence ≥150/100 000 or 
sub-Saharan Africa) when they first register with primary 
care,31 screening migrants for individual conditions 
(latent TB only) at the time of primary care registra-
tion potentially fails to address the range of infectious 
diseases prevalent in-migrant populations. Therefore, 
there is a need to explore city-wide coordinated testing 
for a range of infectious diseases in migrant populations 
at the time of new patient registration with primary care, 
assess the cost effectiveness of this approach and use qual-
itative approaches to understand views towards testing. 
This would, for the first time, allow us to determine the 
acceptability, effectiveness and cost-effectiveness of such a 
combined infectious diseases migrant health programme 
in primary care.
AIMs And objECtIvEs
1. Determine the impact of screening in primary care for 
latent TB, HIV, hepatitis B and hepatitis C on the iden-
tification of these conditions in migrants.
2. Determine the impact of programmatic routine testing 
in primary care for latent TB, HIV, hepatitis B and hep-
atitis C on the number of tests performed on migrants 
for these conditions.
3. Estimate the prevalence of latent TB, HIV, hepatitis B 
and hepatitis C in a cohort of migrants.
4. Explore the knowledge, attitudes and practices of pri-
mary care staff about testing migrants for a range of 
infectious diseases in primary care.
5. Explore the knowledge, attitudes and practices of mi-
grants about infectious diseases and the testing pro-
gramme in primary care.
6. Estimate the cost-effectiveness of primary care based 
testing of migrants for latent TB, HIV, hepatitis B and 
hepatitis C.
MEthods
Work package 1: observational cohort study with interrupted 
time-series analysis (objectives 1–3)
Study design
Observational cohort study utilising primary care data 
before and after the introduction of a migrant screening 
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service in primary care in Leicester, UK. Assessment of 
the screening service’s impact will be with interrupted 
time-series (ITS) analyses of testing numbers. ITS is a 
powerful quasi-experimental design used to assess the 
impact of health/public policy interventions introduced 
at a specific time-point where random assignment is not 
possible.32 33 We have followed published guidance in 
designing this study.33 34
study setting
General practices (n=65) in Leicester, UK participating 
in the migrant screening service. Leicester is among the 
most ethnically diverse UK cities with 34% of the popu-
lation (307 000 in 2011) born overseas3; individuals from 
the Indian subcontinent make up 15% of the population.3
study duration
48 months.
study population
Adult overseas-born migrants registering with one of the 
participating practices in Leicester, UK.
Participant inclusion criteria
 ► Age ≥16 years.
 ► Arrival in the UK ≤5 years.
 ► Overseas-born.
 ► Country of birth TB incidence ≥150/100 000 or 
sub-Saharan Africa or Refugee/Asylum seeker.
Participant exclusion criteria
 ► Tourists visiting the UK.
 ► Migrants aged <16 years.
study synopsis/investigative plan
Proposed migrant screening service in Leicester
As part of NHS care, general practices in Leicester 
commenced migrant screening for latent TB, HIV, hepa-
titis B and hepatitis C from April 2016. This will be the 
standard-of-care whereby overseas-born individuals 
aged 16–65 with UK arrival within the last 5 years from a 
country with TB incidence ≥150/100 000 or from sub-Sa-
haran Africa or a refugee/asylum seeker will be identified 
by staff at the time of general practice (GP) registration/
new patient health check (using template prompts) and 
offered blood-tests for HIV, hepatitis B and hepatitis C. 
Migrants aged 16–35 will also be offered an interferon 
gamma release assay (IGRA) blood-test (QuantiFERON 
Gold in-tube) for latent TB. No other interventions are 
planned during this period.
Laboratory results will be sent to the participant’s 
general practitioner. Migrants testing positive for any of 
the infectious diseases will be referred to secondary care 
for further management using standard referral pathways.
Measurements and data collection
To ensure data collection complies with information gover-
nance processes Leicester City Clinical Commissioning 
Group and the Arden and Greater East Midlands-Com-
missioning Support Unit (AGEM-CSU) are involved. The 
GEM-CSU is a designated Data Services for Commissioners 
Regional Office for primary and secondary care data 
(approved safe haven).
Prior to data collection, we will work with the 
AGEM-CSU to ensure data-sharing agreements are in 
place with participating practices to provide pseudony-
mised/anonymised patient data.
Following data-sharing agreements and approvals, 
we will collect GP registration/consultation data on a 
monthly basis for 87 time-points in total: 60 time-points 
(5 years at monthly-intervals) before the screening-ser-
vice (intervention) commenced (retrospective data 
collection—January 2011 to March 2016) and 30 time-
points (2 years and 3 months at monthly-intervals) after 
the screening-service (prospective data collection—
April 2016 to October 2018). As the screening service 
commences in April 2016, the 3-month period following 
this (April–June 2016) will be considered a transition/
lag period and excluded from data analysis (thus 27 time-
points will be analysed in the post-intervention period).
Data will be downloaded from practices by the 
AGEM-CSU. Primary care searches will be linked to Flag-4 
indicators which allows one to identify new migrants. All 
data will then be anonymised with no personal identifi-
able details. Data will be encrypted prior to being supplied 
(by secure  nhs. net email) to the analysts. Data storage will 
comply with the European Union General Data Protec-
tion Regulation.
Variables that will be collected from GP registra-
tion/consultation data for all migrants registering with 
primary care and eligible for the screening-service will 
include: practice-level data, demographics (age, gender, 
country of birth, dates of arrival and registration), which 
tests were performed (communicable diseases testing: 
latent TB, HIV, hepatitis B and hepatitis C; non-commu-
nicable disease testing: haemoglobin, kidney function 
[GFR and serum creatinine], vitamin D, lipid profile, 
HbA1c, glucose, height/weight/body mass index, blood 
pressure), and the results of these tests. This will there-
fore provide information on the numbers of eligible 
migrants registering with primary care, the numbers of 
migrants tested with the different tests and the number 
of positive tests (and therefore diagnoses) in the cohort. 
As a control, over the same time-periods, we will collect 
migrant testing and diagnosis data for syphilis which is 
not included in the screening service.
statistical analysis
Power and sample size calculations
Sample size/power calculations in an ITS design are 
based on the number of time-points at which data will be 
collected. Generally, 10–12 time-points before and after 
the introduction of the intervention are required. We 
will have 60 time-points before and 27 (24 excluding the 
3-month lag period) time-points after the screening-ser-
vice is introduced which should allow sufficient power.
Since no closed-form expressions are available for 
ITS methods, we also conducted simulations to estimate 
power with the following parameters for the change in 
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the outcome rates: outcomes assessed 60 months before 
and 27 months after screening-service commenced:
 ► An expected sudden level change.
 ► 0.5 positive autocorrelation.
 ► α=0.05.
Under these assumptions, we have more than 86% 
power with an expected effect size of over 2 (monthly 
latent TB diagnostic rate increasing from 100/1000 
tested/month to 200/1000 tested/month).35 In addition, 
large numbers (3500/year) of registering migrants will be 
eligible for testing and approximately 20%–40% of those 
tested will have latent TB. We selected latent TB diagnoses 
as the primary outcome as the prevalence is high and it is 
a public-health concern; the study is suitably powered for 
this evaluation.
Analysis plan
The primary analysis will be the change in the number 
and rate of new latent TB diagnoses in the migrant popu-
lation following the introduction of programmatic infec-
tious disease testing in migrants when registering with 
primary care. This will be undertaken using segmented 
regression. The unit of analysis will be the individual 
patient.
Data will be analysed in several steps:
1. We will describe the cohort focusing on the numbers 
of migrants registering and their demographics.
2. We will compute the absolute numbers, proportion 
(number of migrants tested for each infectious disease 
divided by the number of eligible migrants register-
ing) and rate (average number of eligible migrants 
tested/1000 migrants registering/year) of migrants 
tested for each of the infectious diseases of interest (la-
tent TB, HIV, hepatitis B and hepatitis C) separately. 
Data will be calculated for the overall study period and 
separately for the pre-intervention and post-interven-
tion periods. To ascertain the impact of coordinated 
testing, we will calculate the numbers and proportions 
of eligible migrants who accept testing for all of the 
infectious diseases in the different time periods.
3. We will calculate, at each monthly time-point, the abso-
lute numbers, proportion (number of migrants tested 
divided by the number of eligible migrants registering 
in the month) and testing rate (average number of 
eligible migrants tested in the month/1000 migrants 
registering/month) for each of the infectious diseases.
4. For each infectious disease we will compute the ab-
solute numbers, proportion positive (number of mi-
grants testing positive divided by the number of eligi-
ble migrants tested; this will be the prevalence of the 
individual diseases in the migrant cohort) and rate (av-
erage number of positive tests/1000 migrants tested/
year) of migrants diagnosed with latent TB, HIV, hep-
atitis B and hepatitis C (separately). Data will be calcu-
lated for the overall study period and separately for the 
pre-intervention and post-intervention periods. Co-in-
fection (testing positive for more than one infectious 
disease) will also be calculated (numbers and rate).
5. We will calculate, at each monthly time-point, the ab-
solute numbers of new diagnoses, proportion of pos-
itive test results (number of migrants testing positive 
divided by the number of eligible migrants tested in 
the month) and monthly positive diagnosis rate (aver-
age number of positive test results in the month/1000 
migrants tested/month) for each of the infectious dis-
eases.
6. To investigate factors associated with accepting testing, 
and testing positive, for each/any of the infectious dis-
eases we will undertake logistic regression modelling.
7. To determine the effect of the screening-service, 
trends in the monthly number and rate of testing and 
diagnoses for latent TB, HIV, hepatitis B and hepati-
tis C (separately) will be examined using ITS analyses. 
As a control we will also analyse trends in the monthly 
number and rate of migrant testing and diagnosis for 
syphilis. The study period will be eighty-seven calendar 
months: 60 time-points before and 27 time-points (24 
excluding the 3-month lag period between January and 
March 2016) after the screening-service is introduced. 
The effect of the new testing policy will be assessed us-
ing segmented regression analyses.30 36 Correlation will 
be assessed with the Durbin-Watson statistic and if sig-
nificant, we will use autoregressive integrated moving 
average models.30
8. We will use the data from the fully anonymised infec-
tious diseases testing (including TB, HIV, hepatitis B 
and hepatitis C) to estimate the yields for testing from 
different countries and levels of infection prevalence. 
We will then go on to undertake logistic regression 
modelling to assess factors associated with test positivi-
ty. In addition, we will use the data on test positivity to 
develop theoretical testing algorithms and subsequent-
ly assess their sensitivity and specificity to identify in-
fections. We will not be implementing the theoretical 
algorithms in clinical practice as part of this work.
We will use the non-communicable disease testing 
data (in conjunction with the communicable/infectious 
diseases testing data) to estimate the prevalence of multi-
morbidity with communicable and non-communicable 
diseases in a cohort of migrants.
Analyses will use Stata V.15.0 (StataCorp). Tests are two 
tailed; p values ≤0.05 significant.
Work package 2: qualitative study of the views of primary 
care staff and migrants (objectives 4 and 5)
In order to evaluate the screening programme’s feasibility 
and acceptability to those involved a concurrent qualita-
tive study is essential.
study duration
48 months.
design and methodology
This iterative qualitative study will progress through three 
phases, with each phase informing the next.
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Phase 1
Focus groups will be conducted with people from a range 
of migrant groups, typical to Leicester’s diverse popula-
tion. Notably, these individuals do not need to have been 
invited to the testing programme. Purposive sampling will 
seek to reach migrants from each relevant country-of-or-
igin who have been offered screening (including those 
who accepted and declined) and widening to include 
further participants from each migrant group. Recruit-
ment methods will include invitation via practices (direct/
postal), posters/leaflets, community contacts and snow-
balling where necessary for hard-to-reach groups. We will 
liaise with local healthcare and third sector organisations 
to recruit participants. Staff from these organisations and 
translators (when needed) will assist our focus group 
moderators with facilitation and translation of focus 
groups. We anticipate a sample size of 32–80 (8–10 focus 
groups of 4–8 participants). 
The aim of the focus groups is to explore the views and 
experiences of people from the likely migrant population 
groups in Leicester that may be invited to be tested, about 
(any) health screening checks that they are aware, or 
have experience of, and their (hypothetical) views about 
attending the combined diseases testing programme and, 
if time, the four specific diseases. Focus groups will be 
loosely informed around a topic guide, while recognising 
the need to be flexible, particularly when levels of English 
language are likely to be variable. Focus group discussions 
are likely to inform subsequent focus groups, by high-
lighting salient issues to be further explored. Further, 
the findings may inform the topics and issues explored in 
phases 2 and 3.
Phase 2
Individual interviews will be conducted with staff working 
in healthcare—directly or indirectly involved in part of 
the testing pathway. Purposive sampling will seek to reach 
a range of staff in terms of professional role and stage 
of pathway (eg, primary care [testing], secondary care 
[treatment] and public health). Recruitment will be via 
direct invitation (with accompanying information leaflet 
and opt-in reply slip). We anticipated a sample size of 
20–30. 
The semi-structured interviews will be informed by a 
flexible topic guide to explore their views and experiences 
of the testing programme, including feasibility issues.
Phase 3
Individual interviews will be conducted with individuals 
receiving treatment, having tested positive for one or 
more of the conditions through the testing programme. 
Purposive sampling will seek to reach a range of partic-
ipant in terms of demographics. Individuals attending 
clinics will be recruited by a research nurse while in clinic.
Semi-structured interviews will be informed by a flex-
ible topic guide and will explore the participant’s views 
and experience of the testing programme and views about 
the four specific diseases. Notably, the interviewer will not 
know the health status of the interviewee; the interviewee 
will choose how much to disclose.
We anticipate a sample size of approximately 20. 
The final sample size for all three phases will depend 
on reaching saturation in terms of key themes.
Analysis
With participants’ consent, all focus groups and inter-
views will be audio-recorded and fully transcribed (with 
simultaneous translation where necessary). Analysis will 
be informed by the constant comparative process37 which 
involves reading and rereading of transcripts, identifica-
tion of themes and patterns, translation of themes into 
codes, then coding of the dataset, with continuous refine-
ment of the coding framework.
Work package 3: integrated health-economic analysis of 
migrant testing in primary care (objective 6)
The economic evaluation integrated into this clinical 
study consists of:
1. Costing study in practices.
2. Evidence synthesis.
3. Economic modelling.
Costing study
Using site-interviews at individual practices and in 
secondary care, we will record resource use linked to 
screening and subsequent management of migrants 
testing positive for any of the diseases. We will record 
activity in natural units (staff-time, facility-costs) and use 
national price-weights to produce costs for each activity. 
These will then be summed to create total costs per 
practice which will be used to create an average cost per 
patient. The perspective taken will be that of the NHS; 
national price-weights will ensure results are applicable 
to the whole NHS. The data will inform the modelling 
process.
Evidence synthesis
We will use relevant literature to collect data on costs, 
outcomes, model structure and parameters for our deci-
sion model. In addition, we will elicit expert opinion on 
the study results and literature analysis. Once we have 
estimates for costs, outcomes, model structure and key 
parameters, we will begin the modelling process.
Economic modelling
Study data and outcomes of the evidence synthesis will 
inform our modelling to generate cost-effectiveness 
estimates for the intervention. We envisage adopting a 
Markov modelling approach, given the long-term nature 
of many of the outcomes, but final choice of model struc-
tures will be informed by the evidence synthesis exercise. 
Independent models will be designed and constructed for 
each of the four infectious diseases, aligned in structure 
as much as possible, and model outputs will be analysed 
separately and then in combination, to assess the effective-
ness and cost-effectiveness of the entire programme. The 
models will evaluate outcomes including quality-adjusted 
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life years (QALYs) gained by earlier diagnosis of infec-
tions as a result of the intervention, and infection-specific 
outcomes such as number of active TB cases prevented, 
and numbers of HIV and TB transmissions averted. The 
models will each simulate the screening of a hypothetical 
cohort of migrants for infectious diseases and analyse 
outcomes over a 20-year time horizon and beyond. Effec-
tiveness estimates will be generated by comparing these 
outcomes to simulations modelling the status quo that is, 
in the absence of the intervention. Models will be popu-
lated with costs, outcomes and probabilities taken directly 
from the study, supplemented by data and evidence from 
the literature and expert opinion. Costs and health 
outcomes will be discounted at an annual rate of 3.5% 
which reflects NICE recommendations.38 Economic 
evaluation allows comparison of all relevant options, 
and so in addition we will evaluate the cost-effectiveness 
of targeted screening of migrants (including choice of 
infections to screen/test) according to their countries of 
origin. We will present the results as incremental cost-ef-
fectiveness ratios and use cost-effectiveness acceptability 
curves to present visually a comparison of our estimates of 
the cost-effectiveness of the intervention against possible 
values of the threshold of cost-effectiveness (in particular 
NICE recommendations for cost-effectiveness). Multi-
variable sensitivity analysis will be employed to generate 
uncertainty ranges for each model output (such as QALYs 
gained) and will be expressed as 95% uncertainty inter-
vals. The impact of uncertainty in model inputs will be 
further explored using both one-way and probabilistic 
uncertainty analysis, to evaluate the impact that changes 
in parameters (eg, sensitivity and specificity of diagnostic 
tests) will have on estimates of costs, effects and associ-
ated incremental cost-effectiveness ratios (ICERs).
Analysis and results
Policy recommendations informed by effectiveness and 
cost-effectiveness estimates and sensitivity analysis results 
will be made along with suggestions for further research. 
The cost-effectiveness model will be constructed and 
analysed, using R (The R Foundation for Statistical 
Computing). Cost-effectiveness analyses will be reported 
as per EVEREST guidelines.39
Patient and public involvement
We have undertaken group discussions with migrants to 
get their views on this topic and how we should undertake 
the work. They have been very supportive and provided 
important information about how to take the work 
forward, which topics to concentrate on and how to involve 
people in the study. During the course of the project we 
continue to work with migrants to guide and advise us 
about the work. We have also been working with GPs in 
Leicester to get their views on this testing programme and 
they are have also been highly supportive.
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